Effect of a synthetic analogue of thyronamine on the levels of molecular markers of focal brain damage in an experimental model
Annals of Clinical and Experimental Neurology · 30.06.2026 · 20 (2) · 60-69
DOI: 10.17816/acen.1451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Experimental Neurology, online erschienen am 30.06.2026. Verfasst von Dmitry A. Filimonov und 10 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Therapeutic options for ischemic stroke (IS) are largely limited to reperfusion, underscoring the importance of exploring new approaches to neuroprotection and neurorepair. Thyronamines — endogenous derivatives of thyroid hormones — are a promising class of compounds with putative neuroprotective potential. Study aim: To evaluate the effect of a synthetic thyronamine analog (SA-T0AM) on the levels of brain damage markers in a rat model of experimental IS. Materials and methods. The study was performed on 30 male Wistar rats divided into 4 groups: 1) Experimental — induction of focal cerebral cortical ischemia by application of ferric chloride followed by SA-T0AM administration; 2) Control — induction of ischemia without subsequent therapy; 3) Sham operation — all surgical manipulations except application of ferric chloride (0.9% NaCl solution was used); 4) intact animals. On day 3, concentrations of neuroglobin (NGB), glial fibrillary acidic protein (GFAP), brain-derived neurotrophic factor (BDNF), neuron-specific enolase (NSE), and S100B protein were determined in the cerebral hemisphere tissue by enzyme-linked immunosorbent assay (ELISA).
Results
Induction of ischemia led to a significant increase in the levels of all studied damage biomarkers in both hemispheres. Surgical intervention (craniotomy) caused a nonspecific increase in GFAP, NSE, and BDNF in all operated groups compared to intact animals. The key difference between the Experimental and Control groups was found in the non-ischemic hemisphere: administration of SA-T0AM was associated with a statistically significant increase in NGB content.
Conclusion
The observed selective increase in NGB levels in the contralateral hemisphere following SA-T0AM administration indicates the compound’s ability to activate endogenous neuroprotective mechanisms in response to ischemic injury. This effect may be indirect or it may represent an independent direct action of the agent on neuroglobin expression, which requires further investigation. Although no intergroup differences were found for other brain damage markers (GFAP, NSE, S100B), which may be due to insufficient model sensitivity, the data suggest that further study of SA-T0AM is warranted as a pharmacological postconditioning agent in cerebral ischemia.
Zitieren
APA
Filimonov, D. A., Trubnikova, N. N., Kisilenko, I. A., Belotserkovskaya, M. A., Burtseva, A. A., Glebova, A. E., Ishchenko, R. V., Eresko, A. B., Raksha, E. V., Diuba, D. S., & Berdnikovitch, E. S. (2026). Effect of a synthetic analogue of thyronamine on the levels of molecular markers of focal brain damage in an experimental model. Annals of Clinical and Experimental Neurology, 20(2), 60-69. https://doi.org/10.17816/acen.1451
Vancouver
Filimonov DA, Trubnikova NN, Kisilenko IA, Belotserkovskaya MA, Burtseva AA, Glebova AE, et al. Effect of a synthetic analogue of thyronamine on the levels of molecular markers of focal brain damage in an experimental model. Annals of Clinical and Experimental Neurology. 2026;20(2):60-69. doi:10.17816/acen.1451
BibTeX
@article{Filimonov2026,
author = {Filimonov, Dmitry A. and Trubnikova, Nadezhda N. and Kisilenko, Irina A. and Belotserkovskaya, Margarita A. and Burtseva, Anzhelika A. and Glebova, Albina E. and Ishchenko, Roman V. and Eresko, Alexander B. and Raksha, Elena V. and Diuba, Dinara Sh. and Berdnikovitch, Elena S.},
title = {Effect of a synthetic analogue of thyronamine on the levels of molecular markers of focal brain damage in an experimental model},
journal = {Annals of Clinical and Experimental Neurology},
year = {2026},
volume = {20},
number = {2},
pages = {60--69},
doi = {10.17816/acen.1451}
}
EUVIMED